Last reviewed · How we verify
GLPG1690 single ascending doses — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GLPG1690 single ascending doses (GLPG1690 single ascending doses) — Galapagos NV.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GLPG1690 single ascending doses TARGET | GLPG1690 single ascending doses | Galapagos NV | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GLPG1690 single ascending doses CI watch — RSS
- GLPG1690 single ascending doses CI watch — Atom
- GLPG1690 single ascending doses CI watch — JSON
- GLPG1690 single ascending doses alone — RSS
Cite this brief
Drug Landscape (2026). GLPG1690 single ascending doses — Competitive Intelligence Brief. https://druglandscape.com/ci/glpg1690-single-ascending-doses. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab